Dr Caroline Forkin from ICON discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
List view / Grid view
Victoria Rees (European Pharmaceutical Review)
Filter the results
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
J&J have submitted Phase III trial data in their application to the FDA for emergency authorisation of their COVID-19 vaccine candidate.
A Phase I clinical trial has shown that Ad4-H5-VTN, a single-dose, intranasal influenza vaccine, was safe and produced an immune response.
The UK Government has given £7 million of funding for a clinical trial which will investigate whether patients can be given different COVID-19 vaccines for each dose.
In this article, we investigate three of the latest developments in COVID-19 therapeutics that are delivered intranasally.
NICE has issued final guidance recommending Beovu (brolucizumab) to treat wet age-related macular degeneration in adults.
An interim analysis from a Phase III trial of the Sputnik V vaccine has shown it is effective against symptomatic COVID-19.
New findings have shown that there are currently over 4,000 clinical trials taking place investigating potential COVID-19 therapies.
The EMA's CHMP has begun a rolling review of REGN-COV2, Regeneron's COVID-19 antibody candidate, after successful pre-clinical trials.
An interim analysis has shown that the COVID-19 vaccine developed by J&J is safe and effective at preventing the coronavirus in adults.
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
The UK Government has ordered a further 40 million doses of Valneva’s COVID-19 vaccine candidate, to be manufactured in Scotland.
CEPI has opened a new funding opportunity, providing up to $140 million to support additional clinical research on COVID-19 vaccines.
In a Phase II trial, sotorasib was shown to be effective against pre-treated non-small cell lung cancer (NSCLC).